|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/14/20 Biolargo, Inc. 10-Q 6/30/20 61:7.4M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 664K
2: EX-4.22 Instrument Defining the Rights of Security Holders HTML 75K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
5: EX-32 Certification -- §906 - SOA'02 HTML 20K
12: R1 Document And Entity Information HTML 50K
13: R2 Consolidated Balance Sheets (Current Period HTML 139K
Unaudited)
14: R3 Consolidated Balance Sheets (Current Period HTML 32K
Unaudited) (Parentheticals)
15: R4 Consolidated Statements of Operations and HTML 99K
Comprehensive Loss (Unaudited)
16: R5 Consolidated Statement of Stockholders' Equity HTML 157K
(Deficit) (Unaudited)
17: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 130K
18: R7 Note 1 - Business and Organization HTML 30K
19: R8 Note 2 - Summary of Significant Accounting HTML 101K
Policies
20: R9 Note 3 - Lincoln Park Financing HTML 30K
21: R10 Note 4 - Debt Obligations HTML 65K
22: R11 Note 5 - Share-based Compensation HTML 157K
23: R12 Note 6 - Warrants HTML 73K
24: R13 Note 7 - Accounts Payable and Accrued Expenses HTML 29K
25: R14 Note 8 - Noncontrolling Interest - Clyra Medical HTML 47K
26: R15 Note 9 - BioLargo Engineering, Science and HTML 25K
Technologies, LLC
27: R16 Note 10 - Business Segment Information HTML 131K
28: R17 Note 11 - Commitments and Contingencies HTML 25K
29: R18 Note 12 - Subsequent Events HTML 30K
30: R19 Significant Accounting Policies (Policies) HTML 152K
31: R20 Note 2 - Summary of Significant Accounting HTML 66K
Policies (Tables)
32: R21 Note 4 - Debt Obligations (Tables) HTML 49K
33: R22 Note 5 - Share-based Compensation (Tables) HTML 132K
34: R23 Note 6 - Warrants (Tables) HTML 70K
35: R24 Note 7 - Accounts Payable and Accrued Expenses HTML 28K
(Tables)
36: R25 Note 8 - Noncontrolling Interest - Clyra Medical HTML 30K
(Tables)
37: R26 Note 10 - Business Segment Information (Tables) HTML 122K
38: R27 Note 1 - Business and Organization (Details HTML 43K
Textual)
39: R28 Note 2 - Summary of Significant Accounting HTML 77K
Policies (Details Textual)
40: R29 Note 2 - Summary of Significant Accounting HTML 35K
Policies - Credit Concentration (Details)
41: R30 Note 2 - Summary of Significant Accounting HTML 24K
Policies - Inventory (Details)
42: R31 Note 2 - Summary of Significant Accounting HTML 36K
Policies - Stock Options, Valuation Assumptions
(Details)
43: R32 Note 3 - Lincoln Park Financing (Details Textual) HTML 52K
44: R33 Note 4 - Debt Obligations (Details Textual) HTML 90K
45: R34 Note 4 - Debt Obligations - Schedule of Debt HTML 51K
(Details)
46: R35 Note 5 - Share-based Compensation (Details HTML 149K
Textual)
47: R36 Note 5 - Share-based Compensation - Stock Options HTML 83K
(Details)
48: R37 Note 6 - Warrants (Details Textual) HTML 41K
49: R38 Note 6 - Warrants - Warrants Outstanding (Details) HTML 38K
50: R39 Note 6 - Warrants - Assumptions Used to Determine HTML 28K
Fair Value of Warrants (Details)
51: R40 Note 7 - Accounts Payable and Accrued Expenses - HTML 26K
Summary of Accounts Payable and Accrued Expenses
(Details)
52: R41 Note 8 - Noncontrolling Interest - Clyra Medical HTML 107K
(Details Textual)
53: R42 Note 8 - Noncontrolling Interest - Clyra Medical HTML 29K
Common and Preferred Shares Outstanding (Details)
54: R43 Note 9 - BioLargo Engineering, Science and HTML 42K
Technologies, LLC (Details Textual)
55: R44 Note 10 - Business Segment Information (Details HTML 19K
Textual)
56: R45 Note 10 - Business Segment Information - Segment HTML 82K
Information (Details)
57: R46 Note 11 - Commitments and Contingencies (Details HTML 30K
Textual)
58: R47 Note 12 - Subsequent Events (Details Textual) HTML 87K
60: XML IDEA XML File -- Filing Summary XML 109K
59: EXCEL IDEA Workbook of Financial Reports XLSX 78K
6: EX-101.INS XBRL Instance -- blgo-20200630 XML 2.51M
8: EX-101.CAL XBRL Calculations -- blgo-20200630_cal XML 93K
9: EX-101.DEF XBRL Definitions -- blgo-20200630_def XML 1.33M
10: EX-101.LAB XBRL Labels -- blgo-20200630_lab XML 1.09M
11: EX-101.PRE XBRL Presentations -- blgo-20200630_pre XML 1.34M
7: EX-101.SCH XBRL Schema -- blgo-20200630 XSD 211K
61: ZIP XBRL Zipped Folder -- 0001437749-20-018050-xbrl Zip 189K
EXHIBIT 31.1
Certification of Chief Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Dennis P. Calvert, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of BioLargo, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: August 14, 2020 |
By: |
|
|
Chief Executive Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/14/20 | |||
| For Period end: | 6/30/20 | 4, 4/A, 8-K | ||
| List all Filings | ||||